| Journal Article |
File Downloads |
Abstract Views |
| Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
| "Crises" in medical malpractice insurance: Evidence of excessive price-cutting in the preceding soft market |
0 |
1 |
10 |
20 |
5 |
12 |
45 |
99 |
| A general model of the impact of absenteeism on employers and employees |
1 |
3 |
31 |
66 |
7 |
18 |
120 |
316 |
| Comments on "The Assault on Managed Care: Vicarious Liability, ERISA Preemption, and Class Actions." |
0 |
0 |
0 |
0 |
2 |
6 |
12 |
156 |
| Contingent Fees for Personal Injury Litigation |
1 |
1 |
8 |
64 |
7 |
12 |
83 |
692 |
| Cross-national price differences for pharmaceuticals: how large, and why? |
6 |
10 |
35 |
110 |
9 |
18 |
72 |
214 |
| Does Regulation Drive out Competition in Pharmaceutical Markets? |
0 |
0 |
0 |
2 |
13 |
28 |
158 |
801 |
| Dynamic competition in pharmaceuticals: cross-national evidence from new drug diffusion |
6 |
8 |
31 |
67 |
10 |
18 |
69 |
172 |
| Dynamic competition in pharmaceuticals: cross-national evidence from new drug diffusion |
0 |
3 |
18 |
35 |
1 |
8 |
47 |
96 |
| Holdouts, Externalities, and the Single Owner: One More Salute to Ronald Coase: Comment |
0 |
0 |
0 |
0 |
1 |
6 |
21 |
100 |
| Hospital `profits': The effects of reimbursement policies |
1 |
2 |
8 |
19 |
2 |
10 |
35 |
70 |
| Liability and liability insurance for medical malpractice |
1 |
4 |
22 |
37 |
1 |
14 |
76 |
112 |
| Liability for Medical Malpractice |
3 |
6 |
25 |
101 |
7 |
17 |
47 |
368 |
| Medical negligence and the NHS: an economic analysis |
0 |
0 |
0 |
0 |
4 |
7 |
34 |
86 |
| Mergers and acquisitions in the pharmaceutical and biotech industries |
1 |
3 |
31 |
83 |
2 |
12 |
101 |
258 |
| Mergers and acquisitions in the pharmaceutical and biotech industries |
9 |
21 |
61 |
128 |
15 |
38 |
153 |
310 |
| Price Cutting in Liability Insurance Markets |
0 |
2 |
14 |
52 |
4 |
10 |
38 |
254 |
| Price, Financial Quality, and Capital Flows in Insurance Markets |
0 |
2 |
10 |
48 |
0 |
3 |
17 |
111 |
| Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliances |
0 |
2 |
10 |
71 |
1 |
11 |
55 |
274 |
| Rate Regulation, Safety Incentives, and Loss Growth in Workers' Compensation Insurance |
2 |
3 |
6 |
70 |
2 |
4 |
17 |
612 |
| Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, the Netherlands, and New Zealand |
0 |
0 |
9 |
24 |
1 |
6 |
32 |
114 |
| Separation of the redistributive and allocative functions of government: A public choice perspective |
1 |
4 |
10 |
22 |
6 |
16 |
49 |
142 |
| The Economic Implications of Public Disability Insurance in the United States |
3 |
5 |
8 |
20 |
4 |
8 |
26 |
110 |
| The Economics of Parallel Trade |
2 |
5 |
43 |
51 |
11 |
25 |
126 |
166 |
| The Effects of Malpractice Litigation on Physicians' Fees and Incomes |
0 |
0 |
5 |
36 |
0 |
2 |
16 |
102 |
| The Frequency and Severity of Medical Malpractice Claims |
0 |
0 |
0 |
1 |
10 |
19 |
88 |
420 |
| The Political Economy of Workers' Compensation: Lessons for Product Liability |
0 |
0 |
2 |
5 |
0 |
2 |
6 |
31 |
| The Swedish patient compensation system: Myths and realities |
0 |
0 |
6 |
45 |
3 |
5 |
18 |
109 |
| The impact of price regulation on the launch delay of new drugs-evidence from twenty-five major markets in the 1990s |
2 |
4 |
13 |
23 |
3 |
10 |
34 |
70 |
| Tort Liability: A Minefield for Managed Care? |
0 |
0 |
0 |
0 |
1 |
3 |
14 |
181 |
| Tort Reform: The Case of Medical Malpractice |
0 |
0 |
0 |
0 |
2 |
4 |
29 |
242 |
| Welfare effects of supplementary insurance: a comment |
0 |
0 |
0 |
9 |
1 |
2 |
5 |
36 |
| Worker's Compensation Rate Regulation: How Price Controls Increase Costs |
0 |
0 |
0 |
0 |
4 |
6 |
34 |
366 |
| `The Pros and Cons of a Single Euro-Price for Drugs' and `The Economics of Parallel Trade' |
1 |
1 |
4 |
5 |
3 |
5 |
35 |
39 |
| Total Journal Articles |
40 |
90 |
420 |
1,214 |
142 |
365 |
1,712 |
7,229 |
LogEc is hosted by the
Swedish Business School at Örebro University.